Get the Stockscreener App
34.21
1.30%
0.44
After Hours:
35.13
0.92
+2.69%
Grail Inc stock is traded at $34.21, with a volume of 833.20K.
It is up +1.30% in the last 24 hours and down -33.47% over the past month.
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.
See More
Previous Close:
$33.77
Open:
$33.26
24h Volume:
833.20K
Relative Volume:
0.60
Market Cap:
$1.23B
Revenue:
$117.67M
Net Income/Loss:
$-1.88B
P/E Ratio:
-0.5651
EPS:
-60.5369
Net Cash Flow:
$-621.36M
1W Performance:
-13.87%
1M Performance:
-33.47%
6M Performance:
+12.98%
1Y Performance:
+122.43%
1-Day Range:
$32.91
$35.10
1-Week Range:
$32.91
$41.00
52-Week Range:
$12.33
$63.99
Grail Inc Stock (GRAL) Company Profile
Name
Grail Inc
Sector
Industry
Phone
(833) 694-2553
Address
1525 O'BRIEN DRIVE, MENLO PARK
Compare GRAL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GRAL
Grail Inc
|
34.21 | 1.21B | 117.67M | -1.88B | -621.36M | -60.54 |
|
TMO
Thermo Fisher Scientific Inc
|
467.68 | 180.17B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
197.16 | 146.07B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
534.31 | 46.01B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
114.81 | 33.53B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
185.86 | 32.56B | 15.50B | 1.33B | 2.16B | 7.34 |
Grail Inc Stock (GRAL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-25 | Initiated | Canaccord Genuity | Buy |
| Nov-27-24 | Initiated | Morgan Stanley | Equal-Weight |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Oct-17-24 | Initiated | Guggenheim | Neutral |
Grail Inc Stock (GRAL) Latest News
GRAIL to Present at Canaccord Genuity 45th Annual Growth Conference - Stock Titan
GRAIL LLC Shows Risk Reward Favoring UpsideAI Screening for Swing Trade Picks Finds Momentum - metal.it
GRAIL to Announce Second Quarter 2025 Financial Results - WV News
When is the best time to buy GRAIL LLC stockWeekly Stock Watch With Growth Focus Expanded - beatles.ru
How strong is GRAIL LLC company’s balance sheetRetirement Planning Insights With High Returns - jammulinksnews.com
What markets is GRAIL LLC expanding into Is Cadiz Inc. stock a good long term investment optionDiscover high-impact stocks for your portfolio - jammulinksnews.com
What institutional investors are buying GRAIL LLC stockRapid portfolio appreciation - jammulinksnews.com
How many analysts rate GRAIL LLC as a “Buy”Robust investment performance - jammulinksnews.com
What makes GRAIL LLC stock price move sharplyAchieve consistent double-digit growth rates - jammulinksnews.com
What analysts say about GRAIL LLC stock outlookCapital Preservation Investment Ideas - metal.it
Is GRAIL LLC stock overvalued or undervaluedUnlock the power of real-time market data - jammulinksnews.com
Is GRAIL LLC a good long term investmentExplosive earning power - PrintWeekIndia
What analysts say about GRAIL LLC stockFree Stock Market Real-Time Monitoring - PrintWeekIndia
"The Grail Collection" Could Be a Game-Changer for MDCE (OTC:MDCE)Jordan, Curry, and NBA Royalty Up for Bid - ACCESS Newswire
Minimal Residual Disease Testing Market Trends Analysis Report 2025-2030 | North America Leads in MRD Testing Market with Advanced Reimbursement Ecosystem - GlobeNewswire Inc.
GRAIL LLC Stock Analysis and ForecastBreakout portfolio performance - Autocar Professional
What drives GRAIL LLC stock priceHigh-yield trading alerts - Autocar Professional
Freenome's new CEO is ready to compete in race for tests that can detect cancer earlySan Francisco Business Times - The Business Journals
(GRAL) Technical Data - news.stocktradersdaily.com
Grail posts latest trial data for Galleri cancer detection test - MSN
Grail’s CFO Freidin sells $311k in common stock By Investing.com - Investing.com India
Grail’s CFO Freidin sells $311k in common stock - Investing.com Australia
Grail (GRAL) PT Hiked to $38 at Morgan Stanley amid ‘Equal Weight’ Stance - MSN
GRAIL’s Galleri Multi-Cancer Test Shows Strong Performance in PATHFINDER 2 Study, Paves Way for FDA Submission - MSN
12 Best Young Stocks To Buy and Hold For 5 Years - Insider Monkey
Illumina: A Compelling Buy Despite GRAIL Divestiture and Macroeconomic Challenges - AInvest
Illumina: Higher Profit Margin Despite GRAIL Divestiture And Macroeconomic Headwinds - Seeking Alpha
Grail (GRAL): A High-Reward, High-Risk Play on Cancer Detection's Future - AInvest
15 Successful Spin-Off Companies and Their 2025 Returns - Insider Monkey
GRAIL Insiders Selling US$10m In Stock Relieved As Market Cap Slides To US$1.7b - simplywall.st
GRAIL's Insider Sales: Red Flag or Strategic Move? Assessing Executive Confidence Amid Strong Financials - AInvest
(GRAL) Trading Report - news.stocktradersdaily.com
GRAIL's Exclusion from Russell 1000: A Crossroads for Early Cancer Detection - AInvest
GRAIL, Inc.(NasdaqGS: GRAL) dropped from Russell Midcap Index - MarketScreener
Galleri Early Detection Test May Improve Cancer Detection vs SOC Alone - CancerNetwork
Morgan Stanley raises Grail stock price target to $38 on cancer test potential - Investing.com
Grail plans FDA filing for cancer blood test after new trial - pharmaphorum
Grail reports positive outcomes from registrational study of Galleri test - Yahoo Home
Grail plans to submit updated Galleri blood test for FDA approval next year - Fierce Biotech
Grail stock gains on new data for Galleri cancer test (GRAL) - Seeking Alpha
Grail Inc Stock (GRAL) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):